NEW YORK – Genomic Testing Cooperative (GTC) and Hackensack Meridian Health on Tuesday said that they have partnered to establish an oncology-focused DNA and RNA sequencing laboratory, dubbed Anthology Diagnostics.
The lab, which will be based at Hackensack Meridian JFK University Medical Center in Edison, New Jersey, will perform both next-generation sequencing (NGS) of DNA and RNA from patients' tumor samples as well as analysis of cell-free DNA from liquid biopsies. The collaboration will also allow the Irvine, California-based molecular testing company GTC to co-develop new laboratory tests with Hackensack Meridian Health. The collaboration's aim is to make NGS an element of everyday patient care both within Hackensack's New Jersey-based network of 17 hospitals and 500 care sites, but also along the greater East Coast.
The launch of Anthology Diagnostics builds upon a similar collaboration forged in May 2020 between GCT and the John Theurer Cancer Center at Hackensack to offer NGS to patients treated within the Regional Cancer Care Associates network of physicians across New Jersey, Connecticut, and Maryland.
"We look forward to collaborating with Hackensack Meridian Health through this reference laboratory, which offers sophisticated high-quality molecular testing to strengthen the practice of precision medicine and drive innovation through research and development," GCT's CEO Maher Albitar said in a statement.